两种化疗方案辅助治疗乳腺浸润性导管癌的成本-效果分析

目的：评价注射用表柔比星（法玛新）联合注射用多西他赛注射液（艾素）和注射用紫杉醇脂质体（力朴素）治疗乳腺浸润性导管癌药物成本-效果。方法：回顾某院2016-2017两年期间收治的经组织病理学确诊的乳腺癌患者病历，从中筛选符合标准的患者，使用注射用表柔比星（法玛新）联合多西他赛注射液（艾素）方案的患者为ED组，使用注射用表柔比星（法玛新）联合注射用紫杉醇脂质体（力朴素）方案的患者为EP组，分析比较2组的成本-效果。结果：2组总有效率为74.29%和79.41%，差异无统计学意义（P>0.05）；2组均有不同程度的不良反应，发生率分别为91.43%、73.53%，差异有统计学意义（P<0.05）。ED与EP组的成本-效果比分别为930.70、1218.15，ICER=538 895.27（>3倍人均GDP），ED组具有成本-效果优势。结论：表柔比星联合多西他赛（艾素）与联合紫杉醇脂质体（力朴素）方案治疗浸润性乳腺癌效果相当，但ED组较为经济。

Cost-effectiveness analysis of two adjuvant chemotherapy regimens for breast invasive ductal carcinoma

OBJECTIVE To evaluate the cost-effectiveness of epirubicin hydrochloride for injection (Famaxin) combined with docetaxel injection (Aisu) and paclitaxel liposome injection (Lipusu) in the treatment of breast invasive ductal cancer.METHODS The medical records of patients with breast cancer confirmed by histopathology who were admitted in our hospital from 2016 to 2017 were reviewed, and the patients who met the criteria were screened. The patients who used Epirubicin Hydrochloride for injection (Famaxin) combined with docetaxel injection (Aisu) were classfied as ED group and those who used epirubicin hydrochloride for injection (Famaxin) combined with paclitaxel liposome (Lipusu) regimen were classfied as EP group. The cost-effectiveness of the two groups was analyzed and compared.RESULTS The total effective rates of the two groups were 74.29% and 79.41% with no significant difference (P>0.05); the two groups had different degrees of adverse reactions, and the incidence rates were 91.43% and 73.53%, respectively, and the difference was statistically significant (P<0.05). The cost-effectiveness ratios of ED and EP groups were 930.70 and 1218.15, respectively, with an ICER=538 895.27 > 3 times GDP per capita, and the ED group had a cost-effectiveness advantage.CONCLUSION Epirubicin hydrochloride combined with docetaxel (Aisu) and paclitaxel liposome(Lipusu) regimens have similar efficacy in the treatment of invasive breast cancer, but ED group is more economical.